Edward J Dulac III, EVP, Chief Financial Officer at Intellia Therapeutics, sold NTLA on Jul 2, 2026
Data as of Oct 16
▼ SELL$84.2K4,677 shares at $18.00Edward J Dulac III EVP, Chief Financial OfficerNTLA Intellia Therapeutics, Inc.
- Traded
- Jul 2, 2026
- Disclosed
- Jul 6, 2026
- Filed
- 4 days after the trade
Form 4s are due within two business days.
Official filing (SEC Form 4) ↗
The price around the disclosure
NTLA since disclosure
−36.0%
after the sale
Similar stocks (XLV) since disclosure
+9.1%
XLV — its sector index fund
Change in closing price from Jul 6, 2026 (the first trading day on or after disclosure) to Oct 16, 2026. Dividends excluded. Not a return anyone earned.
Our take
None of our tested rules fired on this trade.